GlobeNewsWire
12 Nov 2025, 21:05 UTC · 44w ago
Verdict
Headline takes no side. We score LYEL +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
LYL273 achieved a 67% confirmed overall response rate and 83% disease control rate with a manageable safety profile in metastatic colorectal cancer patients at the highest dose level studied.
More positive than 99% of claims this week
Lyell acquired exclusive global rights outside of mainland China, Hong Kong, Macau and Taiwan to LYL273, a novel GCC-targeted CAR T-cell therapy for refractory metastatic colorectal cancer.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 87% of claims this week
The FDA granted ronde-cel Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed/refractory LBCL in the second-line setting.
More positive than 84% of claims this week
Enrollment in the Phase 3 head-to-head PiNACLE-H2H trial of ronde-cel for second-line LBCL is expected to begin by early 2026.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported positive clinical data for LYL273 and received an additional RMAT designation from the FDA for ronde-cel.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
−39.3%
Price is moving against the score
$10.71 vs $17.63 close before publication (Nov 12) · not market-adjusted
LYEL chart →
